Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)
Last reviewed: June 19, 2026 Last updated: June 19, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
2005 Dec 15;80(11):1556-9
The absorbance reading at 412 nm was measured at different time points to evaluate the stability of the product
The Bottom Line GLP-1 medications can be a powerful tool for improving metabolic health
For health systems, this means navigating new financial risk, negotiating value-based arrangements and preparing for changes in reimbursement
US$ 20.77
US$ 27.58
US$ 27.84
